Pioneering Therapeutics Targeting Cellular Stress Pathways

Ribon is a clinical-stage biotechnology company dedicated to the discovery and development of first-in-class small molecule inhibitors to block the fundamental ability of cancer cells to survive under stress.

Learn More

Our Approach

Ribon explores novel areas of disease biology and uses deep expertise in drug discovery to advance its pipeline.

Learn More

Our Targets

Our platform enables us to develop first-in-class therapeutics targeting a wide variety of enzymes that use NAD+ as substrate.

Learn More
July 16

Cambridge, MA

Ribon Therapeutics Announces Appointment of Jodie P. Morrison as Chair of the Company’s Board of Directors

Learn More
Join our team of experts.
Find Out More